| Invested through |
|
|---|---|
| Asset Classes | Listed equity |
| Impact strategy | Impact Equities and Bonds |
| ISIN code | CH0012280076 |
| Industry group | Health Care Equipment & Services |
| Aligned with SDGs |
Straumann is a global leader in aesthetic dentistry. The company develops, manufactures, and supplies dental implant systems, biomaterials, computer-aided design and manufacturing prosthetics, digital equipment, software, clear aligner systems (orthodontics) and various materials for dental applications. The company’s client base consists of general dentists, followed by specialists, dental technicians/laboratories, and corporate customers such as distributors, hospitals, universities, and dental service organizations. Straumann began as a research institute in 1954 and is now a global holding company with a staff of 7,340 people, headquartered in Basel, Switzerland, and active in more than 100 countries around the world.
Investment rationale
With its offering of dental implants and related adjacent products, Straumann enhances the well-being and quality of life of people around the world. In recent years the company has expanded to regions with a greater presence of developing countries, and at the same time it has broadened its offering with less expensive products. These geographic and price range expansions increase the accessibility to its products for people with less resources, which reinforces the positive health impact that the company's products deliver.